N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸 | 86060-82-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 赖氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸
• 中文别名: Nα-Fmoc-Nε-Z-L-赖氨酸；Fmoc-Lys(Z)-OH；FMOC-(CBZ)赖氨酸；N-芴甲氧羰基-N-苄氧羰基-L-赖氨酸
• 英文名称: Fmoc-Lys(Z)-OH
• 英文别名: Fmoc-Lys(Cbz)-OH；(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-6-(phenylmethoxycarbonylamino)hexanoic acid
• CAS: 86060-82-4
• 化学式: C₂₉H₃₀N₂O₆
• mdl: MFCD00065662
• 分子量: 502.567
• InChiKey: KRULQRVJXQQPQH-SANMLTNESA-N

物化性质

• 熔点：
  110-120 °C
• 沸点：
  751.2±60.0 °C(Predicted)
• 密度：
  1.261±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  37
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.275
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  29242990
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Fmoc-Lys(Z)-OH
CAS-No. : 86060-82-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
: Nα-Fmoc-Nε-Z-L-lysine
Synonyms
Formula : C29H30N2O6
Molecular Weight : 502,56 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Store under inert gas.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: beige
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 110 - 120 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

简介

N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸是重要药物中间体，用于合成促黄体生成激素(LH)类似物和促性腺激素释放激素(GnRH)高活性类似物。

用途

N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸为L-赖氨酸的N保护化合物，广泛应用于医药及化工中间体的制备。

制备方法

在碱的存在下，9-芴甲氧羰酰氯与N6-Cbz-L-赖氨酸反应得到N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸。此法操作简单、反应条件温和、产率高且适用性广。合成过程如下图所示：

反应信息

• 作为反应物：
  描述：

  N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸 在 氯化亚砜 、 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、100.0 kPa 条件下， 反应 35.0h， 生成 2-(trimethylsilyl)ethyl N²-(9-fluorenylmethoxycarbonyl)-N⁶-{(R)-2-[(2R,4S)-4-(4-methoxybenzyloxycarbonyl)-5,5-dimethylthiazolidin-2-yl]-2-(phenylacetamido)acetyl}-L-lysinate
  参考文献：
  名称：

  生物启发性设计和定向合成的免疫原性位点特别是青霉素化的肽。

  摘要：

  β-内酰胺抗生素过敏被认为是公共健康问题。通过与血清蛋白共价结合，已知青霉素可形成免疫原性复合物。后者被抗原呈递细胞识别并消化成半抗原肽，从而导致被治疗者的免疫接种和包括过敏反应的IgE介导的超敏反应。如果对药物的I型过敏反应通常不可预测，则已知它们依赖于CD4 + T细胞。这项基础研究重新审视了苄青霉素（BP）过敏的化学基础，旨在通过分析结合BP的人血清白蛋白（BP-HSA）概况和评估纯净CD4 +来鉴定具有免疫学意义的仿生苄青霉素酰化肽。T细胞对候选BP-HSA衍生肽的反应。通过质谱研究了在生理和碱性pH下体外合成的BP-HSA生物共轭物的化学结构。从BP半抗原接枝的十个最具代表性的赖氨酸残基中，设计了受HSA启发的15-mer肽序列，并使用两种互补的计算机方法（即HLA II类结合预测）预测了每种肽的潜在T细胞表位特征免疫表位数据库和分析资源（IEDB）中的工具以及计算性丙氨酸扫描诱

  DOI：

  10.1021/acs.bioconjchem.6b00393
• 作为产物：
  描述：

  N-α-9-Fluorenylmethyloxycarbonyl-N-ε-carbobenzoxy-L-lysine methyl ester 在 三丁基氧化锡 作用下， 以 甲苯 为溶剂， 反应 24.0h， 以23%的产率得到N'-芴甲氧羰基-N-苄氧羰基-L-赖氨酸
  参考文献：
  名称：

  N-保护的氨基酸和二肽的苯甲酰基，苄基和甲基酯的选择性脱保护以及与双（三丁基锡）氧化物连接的树脂的N-保护的氨基酸苄基酯的脱保护

  摘要：

  各种N -α-Boc，N -α-Cbz或N，N-二甲基氨基保护的氨基酸和二肽的苯甲酸酯，甲基和苄基酯以及与Wang和Pam树脂连接的N -α保护的氨基酸的酯具有在非质子溶剂中用双（三丁基锡）氧化物有效地和化学选择性地裂解该化合物，从而以良好的收率得到相应的羧酸。此外，已经证明在脱保护过程中不存在外消旋作用。该方法的一个限制是不稳定Ñ -Îμ-Fmoc基团的氨基酸酯8和10，Ñ -α-的Fmoc-大号β-丙氨酸连接于王氏树脂23和Cbz基保护基团在Ñ-α-的Boc-N-Iμ-CBZ-大号赖氨酸苄基和甲酯（5和7），分别与Ñ -α-CBZ-大号-alanyl-大号丙氨酸甲酯19的情况下Ñ -在α-保护的二肽中，没有游离氨基酸的迹象表明该肽键不受影响。

  DOI：

  10.1039/p19960000995

文献信息

• MgI₂-Mediated Chemoselective Cleavage of Protecting Groups: An Alternative to Conventional Deprotection Methodologies
  作者：Mathéo Berthet、Florian Davanier、Gilles Dujardin、Jean Martinez、Isabelle Parrot

  DOI：10.1002/chem.201501799

  日期：2015.7.27

  The scope of MgI2 as a valuable tool for quantitative and mild chemoselective cleavage of protecting groups is described here. This novel synthetic approach expands the use of protecting groups, widens the concept of orthogonality in synthetic processes, and offers a facile opportunity to release compounds from solid supports.

  在此描述了MgI 2作为定量和轻度化学选择性切割保护基的有价值工具的范围。这种新颖的合成方法扩大了保护基的使用范围，拓宽了合成过程中正交性的概念，并提供了从固体载体上释放化合物的简便机会。
• N‐Methylated Peptide Synthesis via Generation of an Acyl N‐Methylimidazolium Cation Accelerated by a Brønsted Acid
  作者：Yuma Otake、Yusuke Shibata、Yoshihiro Hayashi、Susumu Kawauchi、Hiroyuki Nakamura、Shinichiro Fuse

  DOI：10.1002/anie.202002106

  日期：2020.7.27

  formation remains a critical aspect of N‐methylated peptide synthesis. In this study, we synthesized a variety of dipeptides in high yields, without severe racemization, from equivalent amounts of amino acids. Highly reactive N‐methylimidazolium cation species were generated in situ to accelerate the amidation. The key to success was the addition of a strong Brønsted acid. The developed amidation enabled

  牢固的酰胺键形成的发展仍然是N-甲基化肽合成的关键方面。在这项研究中，我们从等量的氨基酸中高收率合成了各种二肽，而没有严重的消旋作用。高反应性的N-甲基咪唑鎓阳离子原位生成以加速酰胺化反应。成功的关键是加入强力的布朗斯台德酸。与常规酰胺化的结果相比，开发的酰胺化使得能够在较短的时间内以较高的产率合成大体积的肽。另外，可以通过使用微流反应器或常规烧瓶来进行酰胺化。天然存在的大体积N-甲基化肽，蝶酰胺I-IV的首次全合成。根据实验结果和理论计算，
• Oxidative couplings on tryptophan-based diketopiperazines leading to fused and bridged chemotypes
  作者：Lorena Mendive-Tapia、Arantxa Albornoz-Grados、Alexandra Bertran、Fernando Albericio、Rodolfo Lavilla

  DOI：10.1039/c7cc00555e

  日期：——

  Selective C–C and C–N oxidative couplings on tryptophan-based diketopiperazines allow the direct access to two novel scaffolds.

  在色氨酸基二酮哌嗪上进行选择性 C-C 和 C-N 氧化偶联，可直接获得两种新型支架。
• Amino acid derivatives as HIV aspartyl protease inhibitors
  申请人：Pharmacor Inc.

  公开号：US06455587B1

  公开（公告）日：2002-09-24

  The present invention relates to a class of amino acid derivatives with HIV aspartyl protease inhibitory properties.

  本发明涉及一类具有HIV天冬氨酸蛋白酶抑制性能的氨基酸衍生物。
• Synthesis of 4-Substituted-3-aminopiperidin-2-ones:  Application to the Synthesis of a Conformationally Constrained Tetrapeptide <i>N</i>-Acetyl-Ser-Asp-Lys-Pro
  作者：Sukeerthi Kumar、Céline Flamant-Robin、Qian Wang、Angèle Chiaroni、N. André Sasaki

  DOI：10.1021/jo050736k

  日期：2005.7.1

  A new and practical synthetic strategy is developed for the synthesis of six-membered lactam-bridged dipeptides, 4-substituted-3-aminopiperidin-2-ones, featuring two key steps: (a) a diastereoselective addition of cuprate to (E)-α,β-unsaturated ester (3) and (b) racemization-free reductive amination. On the basis of this methodology, conformationally constrained tetrapeptide N-acetyl-Ser-Asp-Lys-Pro

  为合成六元内酰胺桥联的二肽4-取代-3-氨基哌啶-2-酮，开发了一种新的实用合成策略，该策略具有两个关键步骤：（a）向（E）-非对映选择性地添加铜酸盐。 α，β-不饱和酯（3）和（b）无消旋的还原胺化。基于该方法，已经成功地由3-氨基-4-乙烯基哌啶-2-酮（22）合成了构象受限的四肽N-乙酰基-Ser-Asp-Lys-Pro（AcSDKP）（2）。